Evidence map›Paper›PMID 32266483›Full record

ReviewCurrent treatment options in oncology2020

Oncolytic Viruses for the Treatment of Metastatic Melanoma.

Megan H Trager, Larisa J Geskin, Yvonne M Saenger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. A Review of Current and Pipeline Drugs for Treatment of Melanoma.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Megan H TragerColumbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.
Larisa J GeskinDepartment of Dermatology, Columbia University, New York, NY, 10032, USA.
Yvonne M SaengerDepartment of Medicine, Division of Hematology Oncology, Columbia University, New York, NY, 10032, USA. yms4@cumc.columbia.edu.
Columbia University · US

Funding

Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)R01FD006108 · FDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SAENGER, YVONNE MARGARET · 2018 to 2020
$750k
A prognostic mRNA immune signature for resected stage II-III melanomaUH2CA218149 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KROLEWSKI, JOHN J., SAENGER, YVONNE MARGARET · 2019 to 2020
$365k
FDA HHS R01 FD006108NCI NIH HHS UH2 CA218149
6 · The paper itself

Abstract

opinion statementThere is an unmet need for additional treatments for metastatic melanoma, besides anti-PD1 antibodies which are FDA approved for adjuvant therapy for stage III or resected stage IV melanoma. Talimogene laherparepvec (T-VEC) is the first and only FDA-approved oncolytic virus for the treatment of melanoma. New viral vectors including coxsackieviruses, HF-10, adenovirus, reovirus, echovirus, and newcastle disease virus are currently under active development and investigation with varying degrees of efficacy in targeting melanoma. The use of T-VEC as a neoadjuvant therapy is emerging, but more data is needed at this point. T-VEC has also shown promise for use in combination therapy with ipilimumab, as T-VEC plus ipilimumab has a significantly higher objective response compared to ipilimumab alone. Data comparing T-VEC in combination with PD-1 checkpoint inhibitors is awaited, and a phase III trial is underway. It is likely that oncolytic viruses will have long-term application in the treatment of melanoma and that T-VEC in particular will continue to have a role in the treatment of patients with readily accessible cutaneous lesions both for local control and synergistic induction of antitumor immunity as part of combination therapies.

Indexed as

Genetic TherapyGenetic VectorsOncolytic VirotherapyOncolytic VirusesCancer VaccinesClinical Trials as TopicCombined Modality TherapyHumansMelanomaNeoadjuvant TherapyNeoplasm MetastasisNeoplasm StagingPrognosisTreatment OutcomeCancer VaccinesMelanomaOncolytic virusTalimogene laherparepvecVaccine

Identifiers

PMID32266483
OpenAlexW3015121259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.